StimCardio has raised $30 million in Series A funding to advance the development of its wearable device designed to treat atrial fibrillation (AFib) through noninvasive nerve stimulation. The round was led by Metis Medtech, with participation from Catalyst Health Ventures, strategic corporate investors and other existing and new backers. The financing will support further clinical research and preparations for regulatory submission.
The company's investigational device, Rhyvive, is a wrist-worn wearable that combines ECG and optical sensors with electrodes that deliver low-level electrical stimulation to the median nerve. This approach is designed to influence nervous system pathways involved in regulating heart rhythm, potentially reducing the recurrence of atrial fibrillation following catheter ablation procedures.
Unlike conventional consumer wearables that primarily detect and monitor irregular heart rhythms, Rhyvive is being developed as an active therapeutic device. The system collects physiological information while delivering noninvasive neuromodulation, with the goal of extending treatment beyond hospital settings and allowing patients to receive ongoing support at home after cardiac procedures.
StimCardio plans to use the funding to advance its NeuroPulse 2 clinical study, a planned multicenter pivotal trial evaluating the safety and effectiveness of the technology. The company is also preparing for a De Novo submission to the U.S. Food and Drug Administration, which would establish a regulatory pathway for the device if clinical evidence supports its intended use.
The investment comes amid growing adoption of wearable health technologies. While smartwatches from companies such as Apple and Google offer ECG monitoring and atrial fibrillation detection, StimCardio aims to move beyond monitoring by delivering therapeutic stimulation. Its approach could represent a new category of wearable cardiac treatment, although the device remains investigational and its effectiveness has not yet been established through pivotal clinical testing.
Click here to read the original news story.
